Matt S.

“Maybe building on a prior question, could you provide any more color on the metrics beyond start forms that you are seeing that support deeper elevitus penetration in the ambulatory patients?”

“Maybe on the MetShera partnership, could you give us your latest thinking on how the acquisition by Pfizer may impact the agreement? I know you've said prior you don't expect this to change anything given there's a change in control clause and that you all collaborate with Pfizer in the past.”

“Maybe first just on CAS to follow up on a prior question. Is it fair to say you guys would consider a commercialization partnership post-peak one or when you're close to reading out peak one, or is that no longer of interest to you?”

“On the gastric digit data, could you share anything on how median PFS is currently tracking? I know you're going to share more next year. And what do you view as a meaningful improvement over the seven to eight months of standard of care?”